Floatz logo

ct103a cells

Autoimmune Diseases of the Nervous System

Tongji HospitalCell therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Autoimmune Diseases of the Nervous System cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Amsterdam UMC, location VUmc
Phase 3B
Tcelna
Opexa Therapeutics, Inc.
Phase 2B
Cyclophosphamide
Indapta Therapeutics, INC.
Phase 1CCC
Fludarabine
Indapta Therapeutics, INC.
Phase 1CCC
MELATONIN
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Phase 1/2CCC
Idp-023
Indapta Therapeutics, INC.
Phase 1CC
Mesna
Indapta Therapeutics, INC.
Phase 1CC
Ocrevus
Indapta Therapeutics, INC.
Phase 1CC

Same molecule, other indications

ct103a cells is also rated in:

idiopathic inflammatory myopathyDormant
C
Indicative ·
39 / 100
View asset →
chronic inflammatory demyelinating polyradiculoneuropathyDormant
C
Indicative ·
39 / 100
View asset →
autoimmune encephalitisDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →